In the current study, we found that treatment of cisplatin-resistant HNSCC with SRC inhibitor, Dasatinib, inhibited the SRC/ETS-1 signaling pathway, thereby leading to further elevation of the IKKβ/NF-κB pathway. This evidence concerns the gene IKBKB and head and neck squamous cell carcinoma.